Gene and drug matrix for personalized cancer therapy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature reviews. Drug discovery

• Publication date

  2010-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd3181-c1PMID 20671766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Third-generation sequencing fireworks at Marco Island

  2010cited by this paper
• Personalized medicine in oncology: the future is now

  2010cited by this paper
• A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

  2010cited by this paper
• The molecular pathology of cancer

  2010cited by this paper
• Pazopanib

  2010cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

  2009cited by this paper
• Inhibition of ALK Signaling for Cancer Therapy

  2009cited by this paper
• Cancer research. Melanoma drug vindicates targeted approach.

  2009cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper

• Enzyme-Nanoparticle Corona: A Novel Approach, Their Plausible Applications and Challenges

  2021cites this paper
• Structure-function relationships of nonviral gene vectors: Lessons from antimicrobial polymers.

  2019cites this paper
• Ligand targeting and peptide functionalized polymers as non-viral carriers for gene therapy.

  2019cites this paper
• Dual Recognition Element Lateral Flow Assay Toward Multiplex Strain Specific Influenza Virus Detection

  2017cites this paper
• Challenges in DNA Delivery and Recent Advances in Multifunctional Polymeric DNA Delivery Systems.

  2017cites this paper
• The challenges associated with molecular targeted therapies for glioblastoma

  2016cites this paper
• Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

  2015cites this paper
• Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines.

  2014cites this paper
• Optimization of personalized therapies for anticancer treatment

  2013cites this paper
• Issues to be considered when studying cancer in vitro.

  2013cites this paper
• FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.

  2013cites this paper
• The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles.

  2013cites this paper
• Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review

  2012cites this paper
• Company profile: Sequenom, Inc.

  2012cites this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012cites this paper
• Future perspectives of personalized medicine in traditional Chinese medicine: a systems biology approach.

  2012cites this paper
• Somatic variation and cancer: therapies lost in the mix

  2011cites this paper
• How can we enable drug discovery informatics for personalized healthcare?

  2011cites this paper
• Predictive biomarkers: a paradigm shift towards personalized cancer medicine

  2011cites this paper
• Does large scale DNA sequencing of patient and tumor DNA yet provide clinically actionable information?

  2010cites this paper